Cats who suffer from the debilitating tooth ailment feline chronic gingivostomatitis (FCGS) can some times experience pain, even after teeth are remove or taking multiple courses of antibiotics or steriods, but scientists who have recently been studying the condition, think the cure could lie in the make up of the cat himself and that a new treatment which draws on the cats’ own stem cells could prove to be the answer in helping animals that are suffering from the disease.
Scientists at the University of California, Davis’ School of Veterinary Medicine enrolled nine cats with FCGS into the pilot study and seven completed treatment.
Each cat received two intravenous injections of 20 million autologous ASCs, one month apart and 71% (five of the seven cats) showed positive results displaying either complete clinical remission (n = 3) or substantial clinical improvement (n = 2).
Scientists behind the study say, "This study is the first to demonstrate the safety and efficacy of fresh, autologous, adipose-derived stem cell systemic therapy for a naturally occurring, chronic inflammatory disease in cats. The findings demonstrate that this therapy resulted in complete clinical and histological resolution or reduction in clinical disease severity and immune modulation in most cats."
This study also identified a potentially useful biomarker that could dictate patient enrollment and shed light on immune modulation mechanism. As a naturally occurring animal model, FCGS also provides a strategic platform for potentially translatable therapy for the treatment of human oral inflammatory disease.
Read more about the study here